News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome

Original Publication Date

December 8, 2025

Article Source

External Web Content

Summary Many veterans and doctors have long questioned whether Agent Orange (AO) exposure during the Vietnam War contributed to cases of myelodysplastic syndrome (MDS), a type of blood cancer. The contaminated chemical is linked to several cancers, but a link to MDS was unclear…

Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers

Original Publication Date

December 7, 2025

Article Source

External Web Content

Chemotherapy-free approaches could offer comparable efficacy with less toxicity (ORLANDO, Dec. 7, 2025) — Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for…

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia

Original Publication Date

November 19, 2025

Article Source

External Web Content

Highlights Heme biosynthesis enzymes are variably suppressed in AML Heme levels are linked with altered leukemic transcriptional programs via BACH1 Heme biosynthesis is a selective dependency in AML, both in vitro and in vivo Heme starvation disrupts complex IV, inducing copper…

Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia

Original Publication Date

November 18, 2025

Article Source

External Web Content

Abstract Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM)…

Outpatient Low-Dose Venetoclax-Azacitidine vs. Intensive Therapy in Newly Diagnosed AML in Resource-Limited Settings

Original Publication Date

November 6, 2025

Article Source

External Web Content

Key points Outpatient low-dose VenAza plus itraconazole reduced early mortality and hospitalizations while maintaining treatment efficacy. VenAza offers a safer, cost-effective alternative to intensive chemotherapy in newly diagnosed AML. Abstract Acute myeloid leukemia (AML)…

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Original Publication Date

November 5, 2025

Article Source

External Web Content

Key Points Ivosidenib, venetoclax ± azacitidine either rapidly selects evolved, resistant leukemic clones or eradicates leukemic clones. Resistant clones express RNA signatures of stemness, branched-chain amino acid metabolism, and menin targets. Subjects:Myeloid Neoplasia…

Cyclophosphamide and Cyclosporin for GVHD Prevention

Original Publication Date

October 1, 2025

Article Source

External Web Content

Curtis et al. (July 17 issue)1 report evidence of longer graft-versus-host disease (GVHD)–free, relapse-free survival with post-transplantation cyclophosphamide–based prophylaxis than with cyclosporin–methotrexate among patients receiving a stem-cell transplant from a matched…

Azacitidine as therapy for VEXAS syndrome

Original Publication Date

September 18, 2025

Article Source

External Web Content

How should patients with VEXAS (an acronym for vacuoles [in myeloid and erythroid precursors], E1 enzyme, X-linked, autoinflammatory, somatic) syndrome be treated? Until now, we have only had case reports and small series to guide us. In this issue of Blood, Jachiet and…

Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis

Original Publication Date

September 18, 2025

Article Source

External Web Content

Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). This systematic review and meta-analysis aims to evaluate the efficacy and safety of luspatercept in LR-MDS. We conducted a systematic review and…

A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs

Original Publication Date

September 17, 2025

Article Source

External Web Content

Highlights • Single-cell RNA-sequencing performed on 16 lower-risk myelodysplastic syndrome (LR-MDS) bone marrow-derived mononuclear cells (BMMCs) • A 30-gene signature distinguishes LR-MDS hematopoietic stem and progenitor cells (HSPCs) from Healthy HSPCs • Vesicular trafficking…

❄️Give the Gift of Answers, Support, and Hope This Holiday Season ❄️

News and Treatment Updates

Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome

Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia

Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia

Outpatient Low-Dose Venetoclax-Azacitidine vs. Intensive Therapy in Newly Diagnosed AML in Resource-Limited Settings

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Cyclophosphamide and Cyclosporin for GVHD Prevention

Azacitidine as therapy for VEXAS syndrome

Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis

A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs

We Recommend

For Patients and Families

Website Feedback

We Recommend

For Patients and Families